Insider trading activities (stock purchases, sales, and option exercises)
reported by insiders of Apellis Pharmaceuticals, Inc. (APLS)
since 2005 are illustrated in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Apellis Pharmaceuticals, Inc. since year 2005.
Table 2 shows the detailed insider transactions of Apellis Pharmaceuticals, Inc. since 2005.
The reporting company's ticker symbol is APLS. The reporting company's CIK number is 1492422.
The total value of stock buying since 2005 is $41,896,898.
The total value of stock sales since 2005 is $565,046.
The total value of stock option exercises since 2005 is $989,662.
|Trading Period||Insider Buying||Insider Sales||Option Exercises|
|Trade Date||Insider Name||Trade Type||Shares||Price ($)||Value ($)|
|2019-08-29||Sullivan Timothy Eugene (Chief Financial Officer)||Buy||11,699||29.71||347,635|
|2019-08-23||Francois Cedric (Chief Executive Officer)||Option Ex||37,505||2.67||100,138|
|2019-08-15||Francois Cedric (Chief Executive Officer)||Sale||10,000||26.87||268,710|
|2019-08-15||Francois Cedric (Chief Executive Officer)||Option Ex||10,000||2.14||21,400|
|2019-08-07||Watson David O. (General Counsel)||Option Ex||5,000||2.67||13,350|
|2019-06-27||Francois Cedric (Chief Executive Officer)||Option Ex||275,000||2.14||588,500|
|2019-03-11||Morningside Venture Investments Ltd (10% Owner)||Buy||441,176||17.00||7,499,992|
|2018-11-14||Grossi Federico (See Remarks)||Option Ex||6,250||3.20||20,000|
|2018-11-14||Axon Steven (Chief Business Officer)||Option Ex||11,500||2.59||29,785|
|2018-09-21||Morningside Venture Investments Ltd (10% Owner)||Buy||40,000||19.84||793,600|
|2018-09-20||Morningside Venture Investments Ltd (10% Owner)||Buy||41,323||19.11||789,682|
|2018-09-19||Morningside Venture Investments Ltd (10% Owner)||Buy||60,000||18.09||1,085,400|
|2018-09-18||Morningside Venture Investments Ltd (10% Owner)||Buy||40,000||18.47||738,800|
|2018-09-17||Morningside Venture Investments Ltd (10% Owner)||Buy||40,000||18.67||746,800|
|2018-09-14||Watson David O. (General Counsel)||Sale||15,776||18.78||296,336|
|2018-09-14||Watson David O. (General Counsel)||Option Ex||32,818||2.67||87,624|
|2018-05-29||Watson David O. (General Counsel)||Option Ex||624||2.67||1,666|
|2018-05-24||Scheibler Lukas (See Remarks)||Buy||2,935||20.37||59,785|
|2018-04-11||Grossi Federico (See Remarks)||Option Ex||8,500||3.20||27,200|
|2018-02-20||Axon Steven (Chief Business Officer)||Option Ex||38,610||2.59||99,999|
|2017-11-13||Venbio Global Strategic Fund Ii L.p. (10% Owner)||Buy||127,515||14.00||1,785,210|
|2017-11-13||Morningside Venture Investments Ltd (10% Owner)||Buy||575,000||14.00||8,050,000|
|2017-11-13||Hillhouse Capital Management, Ltd.||Buy||1,428,571||14.00||19,999,994|
Insider trading activities including stock purchases, stock sales, and option exercises of APLS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Apellis Pharmaceuticals, Inc. (symbol APLS, CIK number 1492422) see the Securities and Exchange Commission (SEC) website.